Advertisement
Screener

XENON PHARMACEUTICALS INC. (XENE) Graph

XENE Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue (m); Revenue including tax $0.00; Research and development $99.22M; Operating expenses $123.16M.
  • 2026-03-31: Revenue (m); Revenue including tax $0.00; Research and development $88.51M; Operating expenses $112.33M.
  • 2025-12-31: Revenue (m); Revenue including tax $0.00*; Research and development $87.70M*; Operating expenses $109.77M*.
  • 2025-09-30: Revenue (m); Revenue including tax $0.00; Research and development $77.05M; Operating expenses $96.34M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

XENE revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$123.16MOperating income-$123.16MResearch & development$99.22MPre-tax income-$111.32MIncome tax-$585.00KNet income-$110.74M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$0.00$99.22M$123.16M-$585.00K-$110.74M
2026-03-31(m)$0.00$88.51M$112.33M-$2.57M-$102.30M
2025-12-31(m)$0.00*$87.70M*$109.77M*$538.00K*-$105.26M*
2025-09-30(m)$0.00$77.05M$96.34M$677.00K-$90.90M
2025-06-30(m)$0.00$74.98M$94.23M-$626.00K-$84.71M
2025-03-31(m)$7.50M$61.20M$80.24M$427.00K-$65.05M
2024-09-30(m)$0.00$56.97M$73.68M-$320.00K-$62.79M
2024-06-30(m)$0.00$49.70M$69.10M-$333.00K-$57.92M
2024-03-31(m)$0.00$44.25M$59.04M$412.00K-$47.93M
2023-09-30(m)(m)$42.88M$55.68M-$157.00K-$48.46M
2023-06-30(m)(m)$44.04M$55.62M-$220.00K-$47.46M
2023-03-31(m)(m)$39.52M$49.05M$290.00K-$41.73M
2022-09-30(m)$132.00K$29.43M$38.26M-$587.00K-$37.15M
2022-06-30(m)$536.00K$22.15M$30.85M-$40.00K-$31.16M
2022-03-31(m)$8.77M$19.36M$26.14M-$394.00K-$19.67M
2021-09-30(m)$8.12M$18.89M$23.72M-$205.00K-$15.45M
2021-06-30(m)$2.22M$18.38M$24.72M-$217.00K-$22.11M
2021-03-31(m)$4.36M$16.31M$20.42M-$68.00K-$15.76M
2020-09-30(m)$6.55M$13.04M$16.25M-$203.00K-$8.86M
2020-06-30(m)$13.38M$10.72M$14.03M-$39.00K-$175.00K
2020-03-31(m)$7.08M$11.79M$15.11M-$1.00K-$7.48M
2019-09-30(m)$3.50M$9.75M$12.45M$5.00K-$8.87M
2019-06-30(m)(m)$8.21M$10.51M-$29.00K-$10.01M
2019-03-31(m)(m)$9.14M$11.76M$37.00K-$11.34M
2018-09-30(m)(m)$6.25M$14.19M-$8.00K-$14.38M
2018-06-30(m)(m)$5.42M$7.59M-$8.00K-$7.80M
2018-03-31(m)(m)$5.57M$7.81M$12.00K-$3.75M
2017-12-31$16.00K(m)(m)(m)(m)-$8.06M
2017-09-30$264.00K(m)$7.16M$8.91M(m)-$7.74M
2017-06-30$15.00K(m)$6.11M$7.91M(m)-$7.38M
2017-03-31$16.00K(m)$5.90M$8.00M(m)-$7.52M
2016-12-31$376.00K(m)(m)(m)(m)-$6.00M
2016-09-30$413.00K(m)$5.96M$7.74M(m)-$7.71M
2016-06-30$413.00K(m)$5.10M$6.78M(m)-$6.02M
2016-03-31$601.00K(m)$4.36M$6.26M(m)-$3.26M
2015-12-31$3.23M(m)(m)(m)(m)-$3.94M
2015-09-30$4.29M(m)$3.79M$5.11M(m)-$3.83M
2015-06-30$4.05M(m)$3.67M$3.85M(m)$1.17M
2015-03-31$4.01M(m)$3.43M$10.15M(m)-$9.16M
2014-12-31$4.88M(m)(m)(m)(m)(m)
2014-09-30$13.19M(m)$3.22M$4.53M(m)$9.19M
2014-06-30$5.30M(m)$2.57M$3.92M(m)$1.23M
2014-03-31$5.00M(m)$2.53M$3.97M(m)$1.37M
2013-12-31$5.58M(m)(m)(m)(m)(m)
2013-09-30$10.79M(m)$2.58M$4.27M(m)$6.38M
2013-06-30$5.60M(m)(m)(m)(m)(m)
2013-03-31$5.38M(m)(m)(m)(m)(m)

Revenue and expense 6 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$0.00$187.73M$235.48M-$3.16M-$213.04M
2025-06-30(m)$7.50M$136.19M$174.47M-$199.00K-$149.75M
2024-06-30(m)$0.00$93.95M$128.15M$79.00K-$105.86M
2023-06-30(m)(m)$83.56M$104.67M$70.00K-$89.19M
2022-06-30(m)$9.30M$41.51M$56.99M-$434.00K-$50.83M
2021-06-30(m)$6.58M$34.69M$45.13M-$285.00K-$37.87M
2020-06-30(m)$20.46M$22.51M$29.14M-$40.00K-$7.66M
2019-06-30(m)(m)$17.34M$22.27M$8.00K-$21.35M
2018-06-30(m)(m)$10.98M$15.40M$4.00K-$11.56M
2017-06-30$31.00K(m)$12.01M$15.91M(m)-$14.90M
2016-06-30$1.01M(m)$9.47M$13.04M(m)-$9.28M
2015-06-30$8.06M(m)$7.10M$13.99M(m)-$7.99M
2014-06-30$10.30M(m)$5.10M$7.89M(m)$2.60M

Revenue and expense 9 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$7.50M$213.24M$270.80M$478.00K-$240.65M
2024-09-30(m)$0.00$150.92M$201.82M-$241.00K-$168.65M
2023-09-30(m)(m)$126.44M$160.36M-$87.00K-$137.65M
2022-09-30(m)$9.43M$70.94M$95.25M-$1.02M-$87.98M
2021-09-30(m)$14.70M$53.58M$68.86M-$490.00K-$53.32M
2020-09-30(m)$27.02M$35.56M$45.39M-$243.00K-$16.51M
2019-09-30(m)$3.50M$27.09M$34.72M$13.00K-$30.22M
2018-09-30(m)(m)$17.23M$29.59M-$4.00K-$25.94M
2017-09-30$295.00K(m)$19.18M$24.82M(m)-$22.64M
2016-09-30$1.43M(m)$15.43M$20.78M(m)-$16.99M
2015-09-30$12.35M(m)$10.89M$19.11M(m)-$11.81M
2014-09-30$23.49M(m)$8.31M$12.42M(m)$11.79M
2013-09-30$21.77M(m)$9.56M$14.08M(m)$9.52M

Revenue and expense 12 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$7.50M$300.94M$380.57M$1.02M-$345.91M
2024-12-31(m)$0.00$210.39M$279.30M-$4.09M-$234.33M
2023-12-31(m)$0.00$167.51M$214.05M-$292.00K-$182.39M
2022-12-31(m)$9.43M$105.77M$138.58M$118.00K-$125.37M
2021-12-31(m)$18.44M$75.46M$97.43M-$6.00K-$78.88M
2020-12-31(m)$32.17M$50.52M$63.47M-$257.00K-$28.84M
2019-12-31(m)$6.83M$38.84M$49.65M-$23.00K-$41.59M
2018-12-31(m)(m)$23.63M$38.04M-$24.00K-$34.50M
2017-12-31$311.00K(m)$25.57M$32.89M(m)-$30.70M
2016-12-31$1.80M(m)$19.83M$26.62M(m)-$23.00M
2015-12-31$15.58M(m)$15.15M$24.94M(m)-$15.75M
2014-12-31$28.37M(m)$11.77M$17.26M$0.00$13.02M
2013-12-31$27.36M(m)$12.30M$17.64M$0.00$12.03M
2012-12-31$14.31M(m)$10.46M$17.46M$0.00-$4.30M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Organon & Co. (OGN)United States$3.603B17.03
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09